Étiquette : psychiatric disorders

Psychedelic science in post-COVID-19 psychiatry, J. R. Kelly et al., 2020

Psychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94   The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]

Lire la suite

Psychedelic psychiatry’s brave new world, Nutt, D., Erritzoe, D., & Carhart-Harris, R., 2020

Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020   After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.   Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]

Lire la suite

Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine, Danilo De Gregorio et al., 2021

Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Danilo De Gregorio, Argel Aguilar-Valles, Katrin H. Preller, Boris Dov Heifets, Meghan Hibicke, Jennifer Mitchell, and Gabriella Gobbi The Journal of Neuroscience,  2021, 41 (5), 891–900. Doi :10.1523/JNEUROSCI.1659-20.2020   A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as [...]

Lire la suite